1) Small molecular inhibitors. The Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers including the discovery and testing of new therapeutic targets and new small molecule inhibitors. Currently the lab focuses on prostate, breast, lung, bladder, oral cancer, and neuroendocrine neoplasms.

2) Small molecular inhibitor screening. The Stoyanova lab utilizes High-Throughput Screening (HTS) to identify new and selective small molecule inhibitors for metastatic cancers.

3) Antibody-based therapies for advanced prostate, breast, lung, bladder, oral and other epithelial cancers. The Stoyanova lab develops and tests antibody-based strategies as targeted therapies. We also construct new antibody-drug conjugates as a therapeutic strategy to deliver toxic agents to the tumor sites.